Senior Vice President, Human Resources · LEXICON PHARMACEUTICALS, INC. (LXRX)

Wendy McDermott

A named executive officer of LEXICON PHARMACEUTICALS in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$1,270,346

FY2024: $1,111,711

5th of 5 named executive officers at Lexicon Pharmaceuticals by FY2025 total.

5 named officers on file for LEXICON PHARMACEUTICALS, FY2025

See an example →

What this number hides

The filing gives the total. LEXICON PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed March 16, 2026 (DEF 14A).

Free

Get Wendy McDermott’s full pay file as a PDF — free

More than this page: up to 10 years of Wendy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Wendy McDermott and every company like it: Velarion Intel, free for 3 days, no card →

Wendy McDermott compensation by year

LEXICON PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as LEXICON PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$344,828$376,575$415,758
Bonus$79,109$106,447$149,835
Stock awards$201,909$337,443$301,060
Option awards$480,923$276,673$388,840
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$13,907$14,573$14,853
Total$1,120,676$1,111,711$1,270,346

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LEXICON PHARMACEUTICALS, INC. DEF 14A filed March 16, 2026, accession 0001062822-26-000056, and prior-year filings.

How this page was built: the LEXICON PHARMACEUTICALS, INC. filed document, accession 0001062822-26-000056. Every figure is read from that document and cited to the page and table it appears in. Filed March 16, 2026.

$1.1M
$1.1M
$1.3M
FY23
FY24
FY25
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU433,180$498,157—
RSU104,633$120,328—
RSU27,697$31,852—
Option7,104—$3.20
Option1,774—$3.94
Option72,702—$2.43
Option85,012—$2.15
Option649,780—$0.69

Per the Outstanding Equity Awards at Fiscal Year-End table in LEXICON PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

LEXICON PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Michael ExtonChief Executive Officer and Director$3,553,953
Craig GranowitzSenior Vice President and Chief Medical Officer$1,755,909
Scott CoianteSenior Vice President and Chief Financial Officer$1,558,246
Brian CrumSenior Vice President and General Counsel$1,500,384
Wendy McDermott · this pageSenior Vice President, Human Resources$1,270,346

The full LEXICON PHARMACEUTICALS compensation record

free company brief

This page is one person within LEXICON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the LEXICON PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order LEXICON PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LEXICON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Wendy McDermott's compensation dossier